CorMedix Inc. (NASDAQ:CRMD) Q4 2025 Earnings Call Transcript March 5, 2026 CorMedix Inc. misses on earnings expectations. Reported EPS is $0.1493 EPS, expectations were $0.86. Operator: Good morning, ...
22 小时
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed ...
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果